{"id":"https://openalex.org/W2734338482","doi":"https://doi.org/10.1182/blood.v128.22.2768.2768","title":"Genetic or CD40L-Mediated Loss of I\u03bab\u03b1 Is Associated with Resistance to the Dual SYK/JAK Inhibitor Cerdulatinib in DLBCL Cell Lines","display_name":"Genetic or CD40L-Mediated Loss of I\u03bab\u03b1 Is Associated with Resistance to the Dual SYK/JAK Inhibitor Cerdulatinib in DLBCL Cell Lines","publication_year":2016,"publication_date":"2016-12-02","ids":{"openalex":"https://openalex.org/W2734338482","doi":"https://doi.org/10.1182/blood.v128.22.2768.2768","mag":"2734338482"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v128.22.2768.2768","doi":"https://doi.org/10.1182/blood.v128.22.2768.2768","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v128.22.2768.2768","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110303299","display_name":"Greg Coffey","orcid":"https://orcid.org/0009-0008-2566-3755","observed_orcids":["https://orcid.org/0009-0008-2566-3755"]},"institutions":[{"id":"https://openalex.org/I4210094896","display_name":"Portola Pharmaceuticals (United States)","ror":"https://ror.org/00r8a6s58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210094896"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Greg P Coffey","raw_affiliation_strings":["Portola Pharmaceuticals Inc, South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Portola Pharmaceuticals Inc, South San Francisco, CA","institution_ids":["https://openalex.org/I4210094896"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008450996","display_name":"Jiajia Feng","orcid":"https://orcid.org/0009-0002-7736-8703","observed_orcids":["https://orcid.org/0009-0002-7736-8703"]},"institutions":[{"id":"https://openalex.org/I4210094896","display_name":"Portola Pharmaceuticals (United States)","ror":"https://ror.org/00r8a6s58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210094896"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jiajia Feng","raw_affiliation_strings":["Portola Pharmaceuticals Inc, South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Portola Pharmaceuticals Inc, South San Francisco, CA","institution_ids":["https://openalex.org/I4210094896"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062327095","display_name":"Sabah Kadri","orcid":"https://orcid.org/0000-0003-0365-6550","observed_orcids":["https://orcid.org/0000-0003-0365-6550"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Sabah Kadri","raw_affiliation_strings":["Department of Pathology, University of Chicago, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pathology, University of Chicago, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062344658","display_name":"Y. Lynn Wang","orcid":"https://orcid.org/0000-0003-0773-1212","observed_orcids":["https://orcid.org/0000-0003-0773-1212"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Y. Lynn Wang","raw_affiliation_strings":["Department of Pathology, University of Chicago, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pathology, University of Chicago, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109874706","display_name":"Pin Lu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Pin Lu","raw_affiliation_strings":["Department of Pathology, University of Chicago, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pathology, University of Chicago, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049498138","display_name":"Shruti Sharma","orcid":"https://orcid.org/0000-0001-8200-108X","observed_orcids":["https://orcid.org/0000-0001-8200-108X"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Shruti Sharma","raw_affiliation_strings":["Department of Pathology, University of Chicago, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pathology, University of Chicago, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102998623","display_name":"Jeremy P. Segal","orcid":"https://orcid.org/0000-0002-0958-3295","observed_orcids":["https://orcid.org/0000-0002-0958-3295","https://orcid.org/0009-0006-8707-7140"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jeremy Segal","raw_affiliation_strings":["Department of Pathology, University of Chicago, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pathology, University of Chicago, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083215091","display_name":"Glenn C. Michelson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210094896","display_name":"Portola Pharmaceuticals (United States)","ror":"https://ror.org/00r8a6s58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210094896"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Glenn Michelson","raw_affiliation_strings":["Portola Pharmaceuticals Inc, South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Portola Pharmaceuticals Inc, South San Francisco, CA","institution_ids":["https://openalex.org/I4210094896"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063895679","display_name":"Anjali Pandey","orcid":"https://orcid.org/0000-0002-0507-0556","observed_orcids":["https://orcid.org/0000-0002-0507-0556"]},"institutions":[{"id":"https://openalex.org/I4210094896","display_name":"Portola Pharmaceuticals (United States)","ror":"https://ror.org/00r8a6s58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210094896"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Anjali Pandey","raw_affiliation_strings":["Portola Pharmaceuticals Inc, South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Portola Pharmaceuticals Inc, South San Francisco, CA","institution_ids":["https://openalex.org/I4210094896"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109282032","display_name":"John T. Curnutte","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210094896","display_name":"Portola Pharmaceuticals (United States)","ror":"https://ror.org/00r8a6s58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210094896"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John T. Curnutte","raw_affiliation_strings":["Portola Pharmaceuticals, Inc., South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Portola Pharmaceuticals, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I4210094896"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5054604221","display_name":"Pamela B. Conley","orcid":"https://orcid.org/0000-0001-9400-6531","observed_orcids":["https://orcid.org/0000-0001-9400-6531"]},"institutions":[{"id":"https://openalex.org/I4210094896","display_name":"Portola Pharmaceuticals (United States)","ror":"https://ror.org/00r8a6s58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210094896"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pamela B. Conley","raw_affiliation_strings":["Portola Pharmaceuticals, Inc., South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Portola Pharmaceuticals, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I4210094896"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5008450996","https://openalex.org/A5049498138","https://openalex.org/A5062327095","https://openalex.org/A5063895679","https://openalex.org/A5083215091","https://openalex.org/A5102998623","https://openalex.org/A5109874706","https://openalex.org/A5110303299"],"corresponding_institution_ids":["https://openalex.org/I40347166","https://openalex.org/I4210094896"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.18303142,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":95},"biblio":{"volume":"128","issue":"22","first_page":"2768","last_page":"2768"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11591","display_name":"NF-\u03baB Signaling Pathways","score":0.8389000296592712,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11591","display_name":"NF-\u03baB Signaling Pathways","score":0.8389000296592712,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.12099999934434891,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.01860000006854534,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/diffuse-large-b-cell-lymphoma","display_name":"diffuse large B-cell lymphoma","score":0.906000018119812},{"id":"https://openalex.org/keywords/ikappabalpha","display_name":"I\u03baB\u03b1","score":0.7289999723434448},{"id":"https://openalex.org/keywords/nf-kappab-signaling","display_name":"NF-\u03baB signaling","score":0.8539999723434448},{"id":"https://openalex.org/keywords/cd40-ligand","display_name":"CD40 ligand","score":0.8479999899864197},{"id":"https://openalex.org/keywords/syk-inhibition","display_name":"SYK inhibition","score":0.6859999895095825},{"id":"https://openalex.org/keywords/jak-inhibition","display_name":"JAK inhibition","score":0.9660000205039978},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.6349999904632568},{"id":"https://openalex.org/keywords/myd88-mutation","display_name":"MYD88 mutation","score":0.6359999775886536},{"id":"https://openalex.org/keywords/card11-mutation","display_name":"CARD11 mutation","score":0.8479999899864197},{"id":"https://openalex.org/keywords/mcl-1","display_name":"Mcl-1","score":0.7940000295639038},{"id":"https://openalex.org/keywords/b-cell-survival","display_name":"B cell survival","score":0.46299999952316284}],"concepts":[{"id":"https://openalex.org/C35174551","wikidata":"https://www.wikidata.org/wiki/Q7660502","display_name":"Syk","level":4,"score":0.7519172430038452},{"id":"https://openalex.org/C2779260929","wikidata":"https://www.wikidata.org/wiki/Q5908266","display_name":"Idelalisib","level":5,"score":0.7234750986099243},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6203793287277222},{"id":"https://openalex.org/C2778453870","wikidata":"https://www.wikidata.org/wiki/Q188930","display_name":"B cell","level":3,"score":0.5796349048614502},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.5000033378601074},{"id":"https://openalex.org/C128240485","wikidata":"https://www.wikidata.org/wiki/Q786998","display_name":"Autocrine signalling","level":3,"score":0.4741984009742737},{"id":"https://openalex.org/C100175707","wikidata":"https://www.wikidata.org/wiki/Q6103519","display_name":"I\u03baB kinase","level":4,"score":0.4494950473308563},{"id":"https://openalex.org/C157695867","wikidata":"https://www.wikidata.org/wiki/Q1100474","display_name":"B-cell receptor","level":4,"score":0.43153178691864014},{"id":"https://openalex.org/C96926380","wikidata":"https://www.wikidata.org/wiki/Q1737968","display_name":"Germinal center","level":4,"score":0.43001270294189453},{"id":"https://openalex.org/C43907098","wikidata":"https://www.wikidata.org/wiki/Q903924","display_name":"breakpoint cluster region","level":3,"score":0.4293658137321472},{"id":"https://openalex.org/C2778690821","wikidata":"https://www.wikidata.org/wiki/Q212354","display_name":"Cytokine","level":2,"score":0.4140756130218506},{"id":"https://openalex.org/C170286685","wikidata":"https://www.wikidata.org/wiki/Q409346","display_name":"B-cell activating factor","level":4,"score":0.41070711612701416},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.3588540852069855},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3563878536224365},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.32956767082214355},{"id":"https://openalex.org/C2777730290","wikidata":"https://www.wikidata.org/wiki/Q411114","display_name":"NF-\u03baB","level":3,"score":0.2990524172782898},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.28210464119911194},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.2804964780807495},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.2753213047981262},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.24970802664756775},{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.22373875975608826},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.16206598281860352},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.14882034063339233}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v128.22.2768.2768","doi":"https://doi.org/10.1182/blood.v128.22.2768.2768","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v128.22.2768.2768","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9391000270843506}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2623214085","https://openalex.org/W2593448801","https://openalex.org/W2534914495","https://openalex.org/W1992320631","https://openalex.org/W1542516598","https://openalex.org/W4293770031","https://openalex.org/W2012678582","https://openalex.org/W2600627839","https://openalex.org/W2895844167","https://openalex.org/W2908420501"],"abstract_inverted_index":{"Abstract":[0],"Abnormal":[1],"upregulation":[2],"of":[3,11,42,67,85,113,122,134,149,180,197,205,254,261,274,294,306,323,373,385,398,406,425,433,438,447,474,497,500,503,510,525,564,585,615,618,628,654,672,682,688],"NF\u03baB":[4,30,57,394,434,557,600],"activity":[5,179,236],"is":[6,31,58,103,332],"observed":[7,154],"in":[8,16,119,156,193,237,271,316,320,336,457,491,625,656,674,677,690],"a":[9,216,272,313,324,333,344,350,507],"variety":[10],"B":[12,55,69,159,694],"cell":[13,70,160,239,256,277,297,358,389,410,414,419,459,477,530,567,659,678,695],"malignancies,":[14],"resulting":[15,319],"proliferative":[17],"and":[18,88,93,128,140,174,225,232,246,265,288,328,408,413,442,517,532,562,593,633],"survival":[19,494],"signals":[20],"that":[21,214,221,282,371,417,534,652],"contribute":[22],"to":[23,52,80,110,125,202,243,286,343,367,379,403,453,463,467,506,546,663],"tumor":[24],"progression.":[25],"Under":[26],"normal":[27],"resting":[28],"conditions,":[29],"negatively":[32],"regulated":[33],"principally":[34],"via":[35,61,195],"its":[36],"physical":[37],"association":[38],"with":[39,158,349,382,431,575,578,692],"I\u03baB":[40,81,86,141],"(inhibitor":[41],"NF\u03baB)":[43],"family":[44,142,228,620],"members,":[45],"thereby":[46],"inhibiting":[47],"nuclear":[48],"transport":[49],"or":[50,105],"access":[51],"DNA.":[53],"In":[54,95,292,347,552],"cells,":[56],"typically":[59],"activated":[60],"various":[62,259],"external":[63,101],"stimuli":[64,102],"(e.g.,":[65],"ligation":[66],"the":[68,98,120,177,226,295,307,321,329,357,369,383,387,418,475,513,523,554,598,607,613,626,669],"antigen":[71],"receptor":[72],"(BCR),":[73],"toll-like":[74],"receptors,":[75,77],"cytokine":[76,199],"CD40),":[78],"leading":[79,201,342],"kinase":[82,219],"complex-dependent":[83],"phosphorylation":[84,437],"members":[87,143,229,621],"targeting":[89],"them":[90],"for":[91,100,268,377,428],"ubiquitination":[92],"degradation.":[94],"some":[96],"cases,":[97],"need":[99],"diminished":[104],"completely":[106,284],"circumvented":[107],"by":[108,145,549,573,605],"mutations":[109,124,151,242],"critical":[111],"regulators":[112,136],"NF\u03baB,":[114,407,586],"as":[115,130,132,138,680],"has":[116,152,622],"been":[117,153,623],"described":[118,290,624],"context":[121,627],"activating":[123],"CD79A/B,":[126],"MYD88,":[127,245],"CARD11,":[129,244],"well":[131],"inactivation":[133,305],"negative":[135],"such":[137],"A20":[139,247],"(reviewed":[144],"Staudt,":[146],"2010).":[147],"Each":[148],"these":[150,673],"clinically":[155],"patients":[157,691],"malignancies":[161],"(Wilson":[162],"et":[163,167,171,186,190,208,249,354,638,642,646],"al,":[164,168,172,187,191,209,250,355,639,643,647],"2012;":[165],"Norenberg":[166,641],"2015;":[169,644],"Mansouri":[170,645],"2015),":[173],"can":[175],"impact":[176,555],"anti-tumor":[178,235],"selective":[181],"BCR":[182],"pathway":[183],"inhibition":[184,469],"(Davis":[185],"2010;":[188],"Wilson":[189],"2012)":[192],"part":[194,681],"induction":[196,584],"autocrine":[198],"stimulation":[200],"JAK/STAT-dependent":[203],"up-regulation":[204],"MCL1":[206],"(Lam":[207],"2008).":[210],"We":[211,364,450,520,665],"previously":[212],"reported":[213],"cerdulatinib,":[215,606],"small":[217],"molecule":[218],"inhibitor":[220],"dually":[222],"targets":[223],"SYK":[224,264],"JAK":[227,266],"JAK1,":[230],"JAK3,":[231],"TYK2,":[233],"maintained":[234],"DLBCL":[238,255,276,476,529,658],"lines":[240,257,278,460,478,531,568,660,679],"bearing":[241],"(Ma":[248],"2015).":[251,648],"The":[252],"majority":[253],"exhibit":[258],"degrees":[260],"reliance":[262],"on":[263,527,556],"signaling":[267,609],"survival,":[269],"however":[270],"screen":[273],"15":[275],"we":[279,650],"found":[280,533],"3":[281,338],"were":[283,570],"resistant":[285,572],"cerdulatinib":[287,689],"are":[289],"here.":[291],"one":[293],"cerdulatinib-resistant":[296],"lines,":[298],"RCK8,":[299],"next":[300],"generation":[301,322,614],"sequencing":[302],"revealed":[303],"bi-allelic":[304],"I\u03baB\u03b1":[308,361,374,401,456,483,511,535,655],"gene.":[309],"One":[310],"allele":[311,331],"carries":[312],"frameshift":[314],"mutation":[315,335,490],"exon":[317,337],"1":[318],"premature":[325],"stop":[326,345],"codon,":[327],"second":[330],"nonsense":[334],"at":[339,512],"Gln154,":[340],"also":[341,588],"codon.":[346],"accord":[348],"previous":[351],"report":[352],"(Kalaitzidis":[353],"2002),":[356],"line":[359,390,420],"lacks":[360],"protein":[362,514],"expression.":[363],"therefore":[365,521],"proceeded":[366],"explore":[368],"possibility":[370],"loss":[372,384,424,499,653],"was":[375,421,435,536,559,581,602],"responsible":[376],"resistance":[378,466,580,662],"cerdulatinib.":[380,664],"Consistent":[381],"I\u03baB\u03b1,":[386],"RCK8":[388,492],"exhibited":[391],"enhanced":[392],"basal":[393],"activity.":[395],"Genetic":[396],"re-introduction":[397],"wild":[399],"type":[400],"led":[402],"rapid":[404],"suppression":[405,432],"ultimately":[409],"cycle":[411],"arrest":[412],"death,":[415],"indicating":[416],"dependent":[422],"upon":[423],"this":[426,579],"gene":[427,484],"survival.":[429],"Associated":[430,577],"decreased":[436],"cellular":[439],"pAKT":[440,591],"S473":[441],"pERK":[443,589],"Y202,":[444],"but":[445,587],"not":[446,582,603],"pSTAT3":[448,594],"Y705.":[449,595],"then":[451],"attempted":[452],"knock":[454,485],"down":[455],"cerdulatinib-sensitive":[458,566],"using":[461],"siRNA":[462],"determine":[464],"if":[465],"SYK/JAK":[468],"could":[470,481],"be":[471,667],"generated.":[472],"None":[473],"tested":[479,569],"(n=4)":[480],"tolerate":[482],"down,":[486],"suggesting":[487],"an":[488,683],"additional":[489],"enables":[493],"under":[495],"conditions":[496],"homozygous":[498],"I\u03baB\u03b1.":[501],"Ligation":[502],"CD40":[504,543],"leads":[505],"transient":[508],"down-regulation":[509],"level":[515],"(Oeckinghaus":[516],"Ghosh,":[518],"2009).":[519],"examined":[522],"effect":[524],"CD40L":[526],"multiple":[528,657],"maximally":[537],"suppressed":[538],"within":[539],"30-60":[540],"minutes":[541],"post":[542],"stimulation,":[544],"returning":[545],"pre-treatment":[547],"levels":[548],"2-4":[550],"hours.":[551],"contrast,":[553],"activation":[558,601],"much":[560],"longer,":[561],"5":[563],"7":[565],"made":[571],"incubation":[574],"CD40L.":[576],"only":[583],"Y204,":[590],"S473,":[592],"Interestingly,":[596],"whereas":[597],"CD40L-induced":[599],"inhibited":[604],"other":[608],"events":[610],"were,":[611],"despite":[612],"resistance.":[616],"Loss":[617],"IkB":[619],"Hodgkin's":[629],"lymphoma,":[630,632],"non-Hodgkin's":[631],"chronic":[634],"lymphocytic":[635],"leukemia":[636],"(Cabannes":[637],"1999;":[640],"Here":[649],"demonstrate":[651],"generates":[661],"will":[666],"exploring":[668],"clinical":[670],"relevance":[671],"vitro":[675],"observations":[676],"ongoing":[684],"phase":[685],"II":[686],"trial":[687],"relapsed/refractory":[693],"malignancies.":[696],"Disclosures":[697],"Coffey:":[698],"Portola":[699,745],"Pharmaceuticals:":[700,710,717,722,732,746,760],"Employment,":[701,711,723,733,747,761],"Equity":[702,712,724,734,743,748,762],"Ownership,":[703,713,725,735,749,763],"Patents":[704,726,736,750,764],"&":[705,727,737,751,765],"Royalties,":[706,728,738,752,766],"Research":[707,714,719,729,739,753,767],"Funding.":[708,715,720,730,740,768],"Feng:Portola":[709],"Wang:Portola":[716],"Honoraria,":[718],"Michelson:Portola":[721],"Pandey:Portola":[731],"Curnutte:3-V":[741],"Biosciences:":[742],"Ownership;":[744],"Funding;":[754],"Sea":[755],"Lane":[756],"Biotechnologies:":[757],"Consultancy.":[758],"Conley:Portola":[759]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2022,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-07-21T00:00:00"}